Teleflex Incorporated

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, ISRG has a market cap of 171.7B. Regarding current trading prices, TFX is priced at $109.23, while ISRG trades at $483.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas ISRG's P/E ratio is 61.28. In terms of profitability, TFX's ROE is -0.24%, compared to ISRG's ROE of +0.16%. Regarding short-term risk, TFX is less volatile compared to ISRG. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check ISRG's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, BDX has a market cap of 58.1B. Regarding current trading prices, TFX is priced at $109.23, while BDX trades at $160.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas BDX's P/E ratio is 26.19. In terms of profitability, TFX's ROE is -0.24%, compared to BDX's ROE of +0.07%. Regarding short-term risk, TFX is more volatile compared to BDX. This indicates potentially higher risk in terms of short-term price fluctuations for TFX.Check BDX's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, TFX is priced at $109.23, while BDXA trades at $59.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas BDXA's P/E ratio is 21.44. In terms of profitability, TFX's ROE is -0.24%, compared to BDXA's ROE of +0.07%. Regarding short-term risk, TFX is less volatile compared to BDXA. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check BDXA's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, ALC has a market cap of 37.9B. Regarding current trading prices, TFX is priced at $109.23, while ALC trades at $77.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas ALC's P/E ratio is 39.29. In terms of profitability, TFX's ROE is -0.24%, compared to ALC's ROE of +0.04%. Regarding short-term risk, TFX is more volatile compared to ALC. This indicates potentially higher risk in terms of short-term price fluctuations for TFX.Check ALC's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, MDLN has a market cap of 33.9B. Regarding current trading prices, TFX is priced at $109.23, while MDLN trades at $41.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas MDLN's P/E ratio is 29.20. In terms of profitability, TFX's ROE is -0.24%, compared to MDLN's ROE of +0.08%. Regarding short-term risk, TFX is less volatile compared to MDLN. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check MDLN's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, RMD has a market cap of 33.7B. Regarding current trading prices, TFX is priced at $109.23, while RMD trades at $230.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas RMD's P/E ratio is 22.81. In terms of profitability, TFX's ROE is -0.24%, compared to RMD's ROE of +0.25%. Regarding short-term risk, TFX is less volatile compared to RMD. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check RMD's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, WST has a market cap of 17.3B. Regarding current trading prices, TFX is priced at $109.23, while WST trades at $240.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas WST's P/E ratio is 35.45. In terms of profitability, TFX's ROE is -0.24%, compared to WST's ROE of +0.17%. Regarding short-term risk, TFX is less volatile compared to WST. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check WST's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, HOLX has a market cap of 16.8B. Regarding current trading prices, TFX is priced at $109.23, while HOLX trades at $75.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas HOLX's P/E ratio is 31.18. In terms of profitability, TFX's ROE is -0.24%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, TFX is more volatile compared to HOLX. This indicates potentially higher risk in terms of short-term price fluctuations for TFX.Check HOLX's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, COO has a market cap of 13.9B. Regarding current trading prices, TFX is priced at $109.23, while COO trades at $71.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas COO's P/E ratio is 35.34. In terms of profitability, TFX's ROE is -0.24%, compared to COO's ROE of +0.05%. Regarding short-term risk, TFX is less volatile compared to COO. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check COO's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, TFX is priced at $109.23, while BDXB trades at $48.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas BDXB's P/E ratio is 7.60. In terms of profitability, TFX's ROE is -0.24%, compared to BDXB's ROE of +0.07%. Regarding short-term risk, TFX is less volatile compared to BDXB. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check BDXB's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, TFX is priced at $109.23, while MASI trades at $175.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas MASI's P/E ratio is 45.80. In terms of profitability, TFX's ROE is -0.24%, compared to MASI's ROE of -0.17%. Regarding short-term risk, TFX is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for TFX.Check MASI's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, BAX has a market cap of 8.8B. Regarding current trading prices, TFX is priced at $109.23, while BAX trades at $17.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas BAX's P/E ratio is -9.77. In terms of profitability, TFX's ROE is -0.24%, compared to BAX's ROE of -0.14%. Regarding short-term risk, TFX is less volatile compared to BAX. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check BAX's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, ATR has a market cap of 8.5B. Regarding current trading prices, TFX is priced at $109.23, while ATR trades at $129.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas ATR's P/E ratio is 21.90. In terms of profitability, TFX's ROE is -0.24%, compared to ATR's ROE of +0.15%. Regarding short-term risk, TFX is more volatile compared to ATR. This indicates potentially higher risk in terms of short-term price fluctuations for TFX.Check ATR's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, RGEN has a market cap of 6.5B. Regarding current trading prices, TFX is priced at $109.23, while RGEN trades at $115.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas RGEN's P/E ratio is 133.85. In terms of profitability, TFX's ROE is -0.24%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, TFX is less volatile compared to RGEN. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check RGEN's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, BLCO has a market cap of 5.8B. Regarding current trading prices, TFX is priced at $109.23, while BLCO trades at $16.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas BLCO's P/E ratio is -16.17. In terms of profitability, TFX's ROE is -0.24%, compared to BLCO's ROE of -0.06%. Regarding short-term risk, TFX is more volatile compared to BLCO. This indicates potentially higher risk in terms of short-term price fluctuations for TFX.Check BLCO's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, AVTR has a market cap of 5.2B. Regarding current trading prices, TFX is priced at $109.23, while AVTR trades at $7.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas AVTR's P/E ratio is -9.76. In terms of profitability, TFX's ROE is -0.24%, compared to AVTR's ROE of -0.09%. Regarding short-term risk, TFX is less volatile compared to AVTR. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check AVTR's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, STVN has a market cap of 4.2B. Regarding current trading prices, TFX is priced at $109.23, while STVN trades at $15.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas STVN's P/E ratio is 26.04. In terms of profitability, TFX's ROE is -0.24%, compared to STVN's ROE of +0.10%. Regarding short-term risk, TFX is less volatile compared to STVN. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check STVN's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, MMSI has a market cap of 4.1B. Regarding current trading prices, TFX is priced at $109.23, while MMSI trades at $69.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas MMSI's P/E ratio is 32.47. In terms of profitability, TFX's ROE is -0.24%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, TFX is less volatile compared to MMSI. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check MMSI's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, ICUI has a market cap of 3.1B. Regarding current trading prices, TFX is priced at $109.23, while ICUI trades at $126.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas ICUI's P/E ratio is 4232.00. In terms of profitability, TFX's ROE is -0.24%, compared to ICUI's ROE of +0.00%. Regarding short-term risk, TFX is less volatile compared to ICUI. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check ICUI's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, WRBY has a market cap of 2.8B. Regarding current trading prices, TFX is priced at $109.23, while WRBY trades at $22.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas WRBY's P/E ratio is 2291.00. In terms of profitability, TFX's ROE is -0.24%, compared to WRBY's ROE of +0.00%. Regarding short-term risk, TFX is less volatile compared to WRBY. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check WRBY's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, HAE has a market cap of 2.8B. Regarding current trading prices, TFX is priced at $109.23, while HAE trades at $59.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas HAE's P/E ratio is 16.45. In terms of profitability, TFX's ROE is -0.24%, compared to HAE's ROE of +0.20%. Regarding short-term risk, TFX is less volatile compared to HAE. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check HAE's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, LMAT has a market cap of 2.5B. Regarding current trading prices, TFX is priced at $109.23, while LMAT trades at $110.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas LMAT's P/E ratio is 43.95. In terms of profitability, TFX's ROE is -0.24%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, TFX is less volatile compared to LMAT. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check LMAT's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, XRAY has a market cap of 2.3B. Regarding current trading prices, TFX is priced at $109.23, while XRAY trades at $11.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas XRAY's P/E ratio is -3.91. In terms of profitability, TFX's ROE is -0.24%, compared to XRAY's ROE of -0.35%. Regarding short-term risk, TFX is less volatile compared to XRAY. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check XRAY's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, ATRC has a market cap of 1.5B. Regarding current trading prices, TFX is priced at $109.23, while ATRC trades at $30.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas ATRC's P/E ratio is -126.83. In terms of profitability, TFX's ROE is -0.24%, compared to ATRC's ROE of -0.02%. Regarding short-term risk, TFX is less volatile compared to ATRC. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check ATRC's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, PLSE has a market cap of 1.5B. Regarding current trading prices, TFX is priced at $109.23, while PLSE trades at $21.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas PLSE's P/E ratio is -20.21. In terms of profitability, TFX's ROE is -0.24%, compared to PLSE's ROE of -0.73%. Regarding short-term risk, TFX is less volatile compared to PLSE. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check PLSE's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, NVCR has a market cap of 1.4B. Regarding current trading prices, TFX is priced at $109.23, while NVCR trades at $12.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas NVCR's P/E ratio is -10.15. In terms of profitability, TFX's ROE is -0.24%, compared to NVCR's ROE of -0.39%. Regarding short-term risk, TFX is less volatile compared to NVCR. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check NVCR's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, QDEL has a market cap of 1.2B. Regarding current trading prices, TFX is priced at $109.23, while QDEL trades at $17.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas QDEL's P/E ratio is -1.06. In terms of profitability, TFX's ROE is -0.24%, compared to QDEL's ROE of -0.46%. Regarding short-term risk, TFX is less volatile compared to QDEL. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check QDEL's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, KMTS has a market cap of 1.1B. Regarding current trading prices, TFX is priced at $109.23, while KMTS trades at $19.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas KMTS's P/E ratio is -4.86. In terms of profitability, TFX's ROE is -0.24%, compared to KMTS's ROE of -1.89%. Regarding short-term risk, TFX is less volatile compared to KMTS. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check KMTS's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, AZTA has a market cap of 963.1M. Regarding current trading prices, TFX is priced at $109.23, while AZTA trades at $20.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas AZTA's P/E ratio is 36.05. In terms of profitability, TFX's ROE is -0.24%, compared to AZTA's ROE of -0.03%. Regarding short-term risk, TFX is less volatile compared to AZTA. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check AZTA's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, NNNN has a market cap of 950.7M. Regarding current trading prices, TFX is priced at $109.23, while NNNN trades at $21.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas NNNN's P/E ratio is 361.00. In terms of profitability, TFX's ROE is -0.24%, compared to NNNN's ROE of +0.11%. Regarding short-term risk, TFX is less volatile compared to NNNN. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check NNNN's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, BLFS has a market cap of 921.6M. Regarding current trading prices, TFX is priced at $109.23, while BLFS trades at $19.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas BLFS's P/E ratio is -76.32. In terms of profitability, TFX's ROE is -0.24%, compared to BLFS's ROE of -0.03%. Regarding short-term risk, TFX is less volatile compared to BLFS. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check BLFS's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, STAA has a market cap of 895.2M. Regarding current trading prices, TFX is priced at $109.23, while STAA trades at $18.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas STAA's P/E ratio is -11.16. In terms of profitability, TFX's ROE is -0.24%, compared to STAA's ROE of -0.23%. Regarding short-term risk, TFX is less volatile compared to STAA. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check STAA's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, TFX is priced at $109.23, while ATRI trades at $459.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas ATRI's P/E ratio is 64.50. In terms of profitability, TFX's ROE is -0.24%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, TFX is more volatile compared to ATRI. This indicates potentially higher risk in terms of short-term price fluctuations for TFX.Check ATRI's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, ANGO has a market cap of 439.8M. Regarding current trading prices, TFX is priced at $109.23, while ANGO trades at $10.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas ANGO's P/E ratio is -15.93. In terms of profitability, TFX's ROE is -0.24%, compared to ANGO's ROE of -0.15%. Regarding short-term risk, TFX is less volatile compared to ANGO. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check ANGO's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, OSUR has a market cap of 228.9M. Regarding current trading prices, TFX is priced at $109.23, while OSUR trades at $3.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas OSUR's P/E ratio is -3.33. In terms of profitability, TFX's ROE is -0.24%, compared to OSUR's ROE of -0.19%. Regarding short-term risk, TFX is less volatile compared to OSUR. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check OSUR's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, UTMD has a market cap of 205M. Regarding current trading prices, TFX is priced at $109.23, while UTMD trades at $64.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas UTMD's P/E ratio is 18.39. In terms of profitability, TFX's ROE is -0.24%, compared to UTMD's ROE of +0.10%. Regarding short-term risk, TFX is more volatile compared to UTMD. This indicates potentially higher risk in terms of short-term price fluctuations for TFX.Check UTMD's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, KRMD has a market cap of 198.7M. Regarding current trading prices, TFX is priced at $109.23, while KRMD trades at $4.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas KRMD's P/E ratio is -53.62. In terms of profitability, TFX's ROE is -0.24%, compared to KRMD's ROE of -0.16%. Regarding short-term risk, TFX is less volatile compared to KRMD. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check KRMD's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, INFU has a market cap of 195M. Regarding current trading prices, TFX is priced at $109.23, while INFU trades at $9.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas INFU's P/E ratio is 30.94. In terms of profitability, TFX's ROE is -0.24%, compared to INFU's ROE of +0.12%. Regarding short-term risk, TFX is less volatile compared to INFU. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check INFU's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, STXS has a market cap of 178.7M. Regarding current trading prices, TFX is priced at $109.23, while STXS trades at $1.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas STXS's P/E ratio is -6.84. In terms of profitability, TFX's ROE is -0.24%, compared to STXS's ROE of -1.92%. Regarding short-term risk, TFX is less volatile compared to STXS. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check STXS's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, SMTI has a market cap of 175.5M. Regarding current trading prices, TFX is priced at $109.23, while SMTI trades at $19.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas SMTI's P/E ratio is -27.28. In terms of profitability, TFX's ROE is -0.24%, compared to SMTI's ROE of -1.28%. Regarding short-term risk, TFX is less volatile compared to SMTI. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check SMTI's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, PDEX has a market cap of 161.9M. Regarding current trading prices, TFX is priced at $109.23, while PDEX trades at $49.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas PDEX's P/E ratio is 14.55. In terms of profitability, TFX's ROE is -0.24%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, TFX is less volatile compared to PDEX. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check PDEX's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, MBOT has a market cap of 124.4M. Regarding current trading prices, TFX is priced at $109.23, while MBOT trades at $2.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas MBOT's P/E ratio is -6.07. In terms of profitability, TFX's ROE is -0.24%, compared to MBOT's ROE of -0.37%. Regarding short-term risk, TFX is less volatile compared to MBOT. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check MBOT's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, NYXH has a market cap of 116.9M. Regarding current trading prices, TFX is priced at $109.23, while NYXH trades at $3.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas NYXH's P/E ratio is -1.21. In terms of profitability, TFX's ROE is -0.24%, compared to NYXH's ROE of -1.01%. Regarding short-term risk, TFX is less volatile compared to NYXH. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check NYXH's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, ZTEK has a market cap of 65.6M. Regarding current trading prices, TFX is priced at $109.23, while ZTEK trades at $0.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas ZTEK's P/E ratio is -10.17. In terms of profitability, TFX's ROE is -0.24%, compared to ZTEK's ROE of -0.61%. Regarding short-term risk, TFX is less volatile compared to ZTEK. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check ZTEK's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, TFX is priced at $109.23, while AKYA trades at $1.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas AKYA's P/E ratio is -1.34. In terms of profitability, TFX's ROE is -0.24%, compared to AKYA's ROE of -6.72%. Regarding short-term risk, TFX is more volatile compared to AKYA. This indicates potentially higher risk in terms of short-term price fluctuations for TFX.Check AKYA's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, DXR has a market cap of 57.1M. Regarding current trading prices, TFX is priced at $109.23, while DXR trades at $11.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas DXR's P/E ratio is 6.91. In terms of profitability, TFX's ROE is -0.24%, compared to DXR's ROE of +0.22%. Regarding short-term risk, TFX is less volatile compared to DXR. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check DXR's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, STSS has a market cap of 56.8M. Regarding current trading prices, TFX is priced at $109.23, while STSS trades at $1.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas STSS's P/E ratio is N/A. In terms of profitability, TFX's ROE is -0.24%, compared to STSS's ROE of -0.91%. Regarding short-term risk, TFX is less volatile compared to STSS. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check STSS's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, TFX is priced at $109.23, while OMIC trades at $20.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas OMIC's P/E ratio is -0.58. In terms of profitability, TFX's ROE is -0.24%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, TFX is more volatile compared to OMIC. This indicates potentially higher risk in terms of short-term price fluctuations for TFX.Check OMIC's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, TFX is priced at $109.23, while IGAP trades at $3.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas IGAP's P/E ratio is -10.52. In terms of profitability, TFX's ROE is -0.24%, compared to IGAP's ROE of +1.21%. Regarding short-term risk, TFX is less volatile compared to IGAP. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check IGAP's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, POCI has a market cap of 33M. Regarding current trading prices, TFX is priced at $109.23, while POCI trades at $4.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas POCI's P/E ratio is -4.59. In terms of profitability, TFX's ROE is -0.24%, compared to POCI's ROE of -0.61%. Regarding short-term risk, TFX is less volatile compared to POCI. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check POCI's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, NEPH has a market cap of 31M. Regarding current trading prices, TFX is priced at $109.23, while NEPH trades at $2.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas NEPH's P/E ratio is 20.86. In terms of profitability, TFX's ROE is -0.24%, compared to NEPH's ROE of +0.12%. Regarding short-term risk, TFX is less volatile compared to NEPH. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check NEPH's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, TFX is priced at $109.23, while SDC trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas SDC's P/E ratio is -0.03. In terms of profitability, TFX's ROE is -0.24%, compared to SDC's ROE of -1.96%. Regarding short-term risk, TFX is less volatile compared to SDC. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check SDC's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, EKSO has a market cap of 27.1M. Regarding current trading prices, TFX is priced at $109.23, while EKSO trades at $11.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas EKSO's P/E ratio is -2.27. In terms of profitability, TFX's ROE is -0.24%, compared to EKSO's ROE of -1.11%. Regarding short-term risk, TFX is less volatile compared to EKSO. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check EKSO's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, TFX is priced at $109.23, while IVC trades at $0.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas IVC's P/E ratio is -0.79. In terms of profitability, TFX's ROE is -0.24%, compared to IVC's ROE of -0.46%. Regarding short-term risk, TFX is less volatile compared to IVC. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check IVC's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, HBIO has a market cap of 22.4M. Regarding current trading prices, TFX is priced at $109.23, while HBIO trades at $5.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas HBIO's P/E ratio is -3.91. In terms of profitability, TFX's ROE is -0.24%, compared to HBIO's ROE of -3.89%. Regarding short-term risk, TFX is less volatile compared to HBIO. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check HBIO's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, MLSS has a market cap of 21.9M. Regarding current trading prices, TFX is priced at $109.23, while MLSS trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas MLSS's P/E ratio is -3.10. In terms of profitability, TFX's ROE is -0.24%, compared to MLSS's ROE of -1.65%. Regarding short-term risk, TFX is less volatile compared to MLSS. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check MLSS's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, RVP has a market cap of 21.5M. Regarding current trading prices, TFX is priced at $109.23, while RVP trades at $0.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas RVP's P/E ratio is -3.26. In terms of profitability, TFX's ROE is -0.24%, compared to RVP's ROE of -0.08%. Regarding short-term risk, TFX is less volatile compared to RVP. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check RVP's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, ZJYL has a market cap of 19.2M. Regarding current trading prices, TFX is priced at $109.23, while ZJYL trades at $2.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas ZJYL's P/E ratio is 12.25. In terms of profitability, TFX's ROE is -0.24%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, TFX is less volatile compared to ZJYL. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check ZJYL's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, FEMY has a market cap of 18.2M. Regarding current trading prices, TFX is priced at $109.23, while FEMY trades at $0.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas FEMY's P/E ratio is -0.90. In terms of profitability, TFX's ROE is -0.24%, compared to FEMY's ROE of -7.64%. Regarding short-term risk, TFX is less volatile compared to FEMY. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check FEMY's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, RGNT has a market cap of 12.5M. Regarding current trading prices, TFX is priced at $109.23, while RGNT trades at $3.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas RGNT's P/E ratio is -0.13. In terms of profitability, TFX's ROE is -0.24%, compared to RGNT's ROE of N/A. Regarding short-term risk, TFX is less volatile compared to RGNT. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check RGNT's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, NXGL has a market cap of 8.6M. Regarding current trading prices, TFX is priced at $109.23, while NXGL trades at $0.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas NXGL's P/E ratio is -2.19. In terms of profitability, TFX's ROE is -0.24%, compared to NXGL's ROE of -0.55%. Regarding short-term risk, TFX is less volatile compared to NXGL. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check NXGL's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, LUCY has a market cap of 5.1M. Regarding current trading prices, TFX is priced at $109.23, while LUCY trades at $1.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas LUCY's P/E ratio is -0.55. In terms of profitability, TFX's ROE is -0.24%, compared to LUCY's ROE of -0.82%. Regarding short-term risk, TFX is less volatile compared to LUCY. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check LUCY's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, TFX is priced at $109.23, while NSTG trades at $0.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas NSTG's P/E ratio is -0.03. In terms of profitability, TFX's ROE is -0.24%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, TFX is less volatile compared to NSTG. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check NSTG's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, NXGLW has a market cap of 3.3M. Regarding current trading prices, TFX is priced at $109.23, while NXGLW trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas NXGLW's P/E ratio is -0.03. In terms of profitability, TFX's ROE is -0.24%, compared to NXGLW's ROE of -0.55%. Regarding short-term risk, TFX is less volatile compared to NXGLW. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check NXGLW's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, MHUA has a market cap of 2.7M. Regarding current trading prices, TFX is priced at $109.23, while MHUA trades at $8.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas MHUA's P/E ratio is 0.28. In terms of profitability, TFX's ROE is -0.24%, compared to MHUA's ROE of +0.06%. Regarding short-term risk, TFX is less volatile compared to MHUA. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check MHUA's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, TFX is priced at $109.23, while GMVD trades at $0.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas GMVD's P/E ratio is -0.01. In terms of profitability, TFX's ROE is -0.24%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, TFX is less volatile compared to GMVD. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check GMVD's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, TFX is priced at $109.23, while GMVDW trades at $7.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas GMVDW's P/E ratio is N/A. In terms of profitability, TFX's ROE is -0.24%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, TFX is less volatile compared to GMVDW. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check GMVDW's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, TFX is priced at $109.23, while AVGR trades at $0.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas AVGR's P/E ratio is -0.05. In terms of profitability, TFX's ROE is -0.24%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, TFX is less volatile compared to AVGR. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check AVGR's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, POAI has a market cap of 1.2M. Regarding current trading prices, TFX is priced at $109.23, while POAI trades at $1.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas POAI's P/E ratio is -0.01. In terms of profitability, TFX's ROE is -0.24%, compared to POAI's ROE of +4.25%. Regarding short-term risk, TFX is less volatile compared to POAI. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check POAI's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, GCTK has a market cap of 641.1K. Regarding current trading prices, TFX is priced at $109.23, while GCTK trades at $1.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas GCTK's P/E ratio is N/A. In terms of profitability, TFX's ROE is -0.24%, compared to GCTK's ROE of -26.59%. Regarding short-term risk, TFX is less volatile compared to GCTK. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check GCTK's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, LUCYW has a market cap of 320.5K. Regarding current trading prices, TFX is priced at $109.23, while LUCYW trades at $0.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas LUCYW's P/E ratio is N/A. In terms of profitability, TFX's ROE is -0.24%, compared to LUCYW's ROE of -0.82%. Regarding short-term risk, TFX is less volatile compared to LUCYW. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check LUCYW's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, WOK has a market cap of 6.8K. Regarding current trading prices, TFX is priced at $109.23, while WOK trades at $1.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas WOK's P/E ratio is N/A. In terms of profitability, TFX's ROE is -0.24%, compared to WOK's ROE of -0.07%. Regarding short-term risk, TFX is less volatile compared to WOK. This indicates potentially lower risk in terms of short-term price fluctuations for TFX.Check WOK's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, ATRS has a market cap of 0. Regarding current trading prices, TFX is priced at $109.23, while ATRS trades at $5.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas ATRS's P/E ratio is 14.95. In terms of profitability, TFX's ROE is -0.24%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, TFX is more volatile compared to ATRS. This indicates potentially higher risk in terms of short-term price fluctuations for TFX.Check ATRS's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, IIN has a market cap of 0. Regarding current trading prices, TFX is priced at $109.23, while IIN trades at $24.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas IIN's P/E ratio is 226.45. In terms of profitability, TFX's ROE is -0.24%, compared to IIN's ROE of -0.00%. Regarding short-term risk, TFX is more volatile compared to IIN. This indicates potentially higher risk in terms of short-term price fluctuations for TFX.Check IIN's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, APR has a market cap of 0. Regarding current trading prices, TFX is priced at $109.23, while APR trades at $37.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas APR's P/E ratio is 22.59. In terms of profitability, TFX's ROE is -0.24%, compared to APR's ROE of +9.81%. Regarding short-term risk, TFX is more volatile compared to APR. This indicates potentially higher risk in terms of short-term price fluctuations for TFX.Check APR's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, HRC has a market cap of 0. Regarding current trading prices, TFX is priced at $109.23, while HRC trades at $155.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas HRC's P/E ratio is 41.92. In terms of profitability, TFX's ROE is -0.24%, compared to HRC's ROE of +0.14%. Regarding short-term risk, TFX is more volatile compared to HRC. This indicates potentially higher risk in terms of short-term price fluctuations for TFX.Check HRC's competition here

TFX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TFX stands at 4.8B. In comparison, ARTC has a market cap of 0. Regarding current trading prices, TFX is priced at $109.23, while ARTC trades at $0.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TFX currently has a P/E ratio of 83.35, whereas ARTC's P/E ratio is N/A. In terms of profitability, TFX's ROE is -0.24%, compared to ARTC's ROE of N/A. Regarding short-term risk, TFX is more volatile compared to ARTC. This indicates potentially higher risk in terms of short-term price fluctuations for TFX.Check ARTC's competition here